

2021 BLOOM BURTON AWARD GALA

September 30, 2021 | 8:00 PM ET





CONTENT

03. **Welcome Letter**

Brian Bloom and Jolyon Burton
Gordon Keller | 2020 Bloom Burton Award Winner

07. **Message from the Prime Minister**

Justin Trudeau

09. **Message from the Premier**

Doug Ford

11. **Message from the Mayor**

John Tory

14. **Finalists**

Daniel Durocher
Carl Hansen
Hamed Shahbazi

21. **Judging Panel**

Michael Altman
Christopher Arendt
Karen Bernstein
Carl Gordon
Dennis Purcell
Melinda Richter
Camille Samuels

WELCOME


Welcome from Bloom Burton & Co.

Thank you for helping us celebrate the 2021 Bloom Burton Award Gala! This is the fifth edition of the Bloom Burton Award and the second consecutive year that we are all together virtually to shine a spotlight on exceptional leaders in the Canadian healthcare sector.


The Bloom Burton Award celebrates someone who demonstrates excellence in the healthcare field and is given to an individual in any role from any field of healthcare and at any stage of development for amazing and impactful work in the immediately preceding year. It's time to recognize and celebrate those who advance medical science, attract or provide risk capital, launch new products or companies, or change policy with a dramatic and positive impact on the world stage.

We received many nominations from the public-at-large and our international and esteemed judging panel has narrowed down and selected three luminary finalists: Daniel Durocher, Scientific Co-Founder of Repare Therapeutics, Carl Hansen, Founder & CEO of AbCellera Biologics, and Hamed Shahbazi, Chairman & CEO of WELL Health Technologies.

We hope that you will be astounded and inspired by these three 2021 Bloom Burton Award finalists and would like you to raise a glass and toast their achievements with us!



Brian Bloom



Jolyon Burton



Bloom Burton Award Gala



ERIN PUGH
Guest Name
Title

2020 BLOOM BURTON AWARD WINNER

GORDON KELLER, PHD

Director, McEwen Stem Cell Institute

Dear Friends and Colleagues:

It's a great pleasure to be able to participate in the presentation of the 2021 Bloom Burton Award, an award that honours outstanding contributions to Canada's healthcare industry. This industry has been undergoing dramatic changes in recent years, fueled in part by remarkable advances in our ability to detect and treat disease. The finalists for this year's award were selected for their innovation and contribution to these advances. My congratulations to each of you for your accomplishments.

When I began my career more than 3 decades ago, I never imagined that findings from a basic research lab would have a direct impact on health care. In my case, this changed with the discovery of pluripotent stem cells. These stem cells enabled one, for the first time, to study human diseases in a petri dish and to develop new regenerative medicine-based therapies to treat them. The path from taking a basic discovery in the research lab to a new therapy in the clinic is challenging and requires a team effort. This effort most often involves collaboration with colleagues in the biotechnology and pharmaceutical industries. More and more of such collaborations are taking place across Canada as scientists in many different disciplines are now working hand-in-hand with companies or starting their own company to accelerate the translation of their discovery to better patient care.

The Bloom Burton Award celebrates these successes. I would like to extend my congratulations to the Bloom Burton team for having the

vision to establish an award to recognize these contributions. I was truly honoured to be the recipient of last year's award; it was a special recognition for myself and my team for the work we've done in developing technologies that we believe will lead to new therapies for heart disease. Given the pace of discovery, there will be many deserving candidates for this award in the years to come and many more celebrations to recognize these successes.

In closing, I would like to again offer my congratulations to the three finalists for the 2021 Bloom Burton Award, your contributions will make a difference.

I wish you all a wonderful evening.

Sincerely,



Gordon Keller, PhD
Director, McEwen Stem Cell Institute





THE RT. HON. JUSTIN P.J. TRUDEAU, P.C., M.P.P
Prime Minister of Canada



PRIME MINISTER • PREMIER MINISTRE

September 30, 2021

Dear Friends:

I am pleased to extend my warmest greetings to everyone attending the 2021 Bloom Burton Award Gala.

Tonight you have gathered to recognize excellence in Canada's innovative healthcare industry. I would like to congratulate the 2021 Bloom Burton Award finalists and wish them the best of luck.



It continues to be a challenging time for planning and hosting events. That is why I would like to thank the organizers for making this year's gala virtual so that it could still take place. You can take pride in your commitment to supporting healthcare in Canada.

Please accept my best wishes for a memorable evening.

Sincerely,

The Rt. Hon. Justin P. J. Trudeau, P.C., M.P.
Prime Minister of Canada



Premier of Ontario - Première ministre de l'Ontario



DOUG FORD

Premier of the Province of Ontario



Premier of Ontario - Premier ministre de l'Ontario

September 30, 2021

A MESSAGE FROM PREMIER DOUG FORD

I want to extend warm greetings to everyone taking part in the Bloom Burton Award Gala. Tonight, you gather for this virtual gala to recognize the scientists, inventors, entrepreneurs, policy makers and leaders who have made the greatest contribution to Canada's health care sector in the past year.

I want to congratulate this year's finalists: Daniel Durocher, the scientific co-founder of Repare Therapeutics; Carl Hansen, the founder and CEO of AbCellera; and Hamed Shahbazi, the Chairman and CEO of WELL Health Technologies. Their achievements are proof that we have some of the best and brightest minds in the world right here in Canada.

Now more than ever, innovation in our health care industry is vitally important — to help us face this unprecedented challenge and prepare us for future crises.

As we work to get Ontario back on track, we will continue to work with our industry partners and invest in innovative made-in-Ontario solutions to help us defeat this deadly virus, strengthen our health care system and lay the foundation for a strong recovery.

Best wishes for a memorable virtual gala.

A handwritten signature in black ink, appearing to read "Doug Ford".

Doug Ford
Premier



JOHN TORY
Mayor of Toronto



Message from the Mayor

It is my pleasure to extend greetings and a warm welcome to everyone participating in the Bloom Burton Award Gala.

I am pleased you have found a way to hold your gala virtually despite the challenges of the COVID-19 pandemic. Congratulations to this year's nominees and award winners who are being recognized for their valuable contributions to Canada's innovative healthcare industry. Through their work, they are helping create advancements in the industry.

The City of Toronto is proud of organizations and individuals that are committed to making a difference and recognizes their contributions to the economic and social well-being of our communities.

On behalf of Toronto City Council, please accept my best wishes for a memorable event and continued success.

Yours truly,

A handwritten signature in blue ink, which appears to read "John Tory". The signature is fluid and cursive.

John Tory
Mayor of Toronto

BLOOM BURTON AWARD GALA

Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year.

Nominees for this year's award were accepted from the biotechnology, pharmaceutical, medical device, diagnostic/ imaging, research instrumentation, consumer health, services and healthcare IT sectors, and equal consideration was given to contributions across all stages of development – from discovery to commercial end markets.

The Bloom Burton Award winner will be chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism.


FINALISTS



Daniel Durocher PhD
Scientific Co-Founder
Repare Therapeutics



Carl Hansen PhD
Founder & CEO
AbCellera Biologics



Hamed Shahbazi
Chairman & CEO
WELL Health Technologies



DANIEL DUROCHER, PHD

Scientific Co-Founder, Repare Therapeutics

Daniel Durocher is a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute where he also acts as Director of the Biomedical Program. He is a Full Professor in the Department of Molecular Genetics at the University of Toronto and a Canada Research Chair (Tier 1) in Molecular Genetics of the DNA Damage Response. Dr. Durocher studied at Université de Montréal and McGill University before undertaking his postdoctoral training at the University of Cambridge. Dr. Durocher's overarching interest lies in understanding how cells maintain genome integrity. His work often employs functional genomics as a tool to chart DNA repair and genome stability processes, with the added aim of discovering novel cancer drug targets. In 2016, Dr. Durocher co-founded Repare Therapeutics with Drs. Frank Sicheri and Agnel Sfeir with key support from Versant Ventures. Repare is an oncology drug discovery company that aims to discover new drugs that target genome instability in cancer based on the principle of synthetic lethality. Repare Therapeutics went public on the Nasdaq stock exchange (ticker: RPTX) in June 2020 and has progressed two molecules in clinical trials: RP-3500, a highly selective inhibitor of the ATR kinase and RP-6306, a first-in-class inhibitor of the PKMYT1 kinase. Dr. Durocher has received numerous awards for his work, including the 2015 Paul Marks Prize from Memorial Sloan-Kettering Cancer Center. He lives in Toronto with his wife Lucy and his daughter Chloë.



CARL HANSEN, PHD

Founder & CEO, AbCellera Biologics

Carl Hansen is AbCellera's founding CEO. Until August 2019, Carl was a Professor at the University of British Columbia, where he co-authored over 65 manuscripts in the fields of microfluidics, immunology, genomics, and nanotechnology. He is an inventor with over 50 US patents and 63 US patent applications that are represented in 7 commercial products. He received the Michael Smith Career investigator award and was recently named one of the "Top 5 Canadian CEOs who elevate their companies." Carl received his PhD in Applied Physics/Biotechnology from Caltech, and a BAsC in Engineering Physics and Honors Mathematics from the University of British Columbia. Before leading AbCellera, he was a scientific Co-Founder of Precision Nanosystems, a Vancouver-based company developing next-generation delivery technology for genetic medicines, and served on the SAB of Fluidigm Corp.



HAMED SHAHBAZI

Chairman & CEO, WELL Health Technologies

Hamed has 20+ years of experience as a technology focused operator. In 1997, he founded TIO Networks (TSXV:TNC), a kiosk solution provider, and transitioned it into a multi-channel payment solution provider, specializing in bill payment and other financial services. In July of 2017, TIO Networks was acquired by PayPal (NASDAQ:PYPL) for CAD\$304 million. Over his career, Hamed has gained extensive experience in strategic mergers, acquisitions, and divestitures, both as an operator (e.g., TIO) and board member (e.g., BBTV, WELL) with more than a dozen successful transactions.

JUDGING PANEL

Michael Altman

Managing Director
Perceptive Advisors

Christopher Arendt

Head, Oncology Therapeutic Area Unit
Takeda

Karen Bernstein

Co-Founder & Chairman
BioCentury Inc.

Carl Gordon

Managing Partner
OrbiMed Advisors

Dennis Purcell

Founder & Senior Advisor
Aisling Capital

Melinda Richter

Global Head
Johnson & Johnson Innovation — JLABS

Camille Samuels

Partner
Venrock



MICHAEL ALTMAN

Managing Director, Perceptive Advisors

Michael Altman joined Perceptive in 2007 and is a managing director on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO and Director of ARYA Sciences Acquisition Corp II & III.

CHRISTOPHER ARENDT

Head, Oncology Therapeutic Area Unit, Takeda

Based at Takeda's Cambridge, Massachusetts, R&D campus, Dr. Arendt is responsible for oversight of Takeda's global Oncology Development portfolio. Since joining Takeda in 2015, Dr. Arendt has helped reshape Takeda's Oncology pipeline with a strong network of global collaborators, emphasizing emerging science leveraging immunological modalities and mechanisms towards curative-intent cancer medicines.





KAREN BERNSTEIN

Co-Founder & Chairman, BioCentury

Karen is Co-Founder and Chairman of BioCentury Inc. and was Editor in Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain, and at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces. Karen also serves on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the Board of Overseers of Scripps Research.

CARL GORDON

Managing Partner, OrbiMed Advisors

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last six years (2014 to 2019) Forbes® Magazine named Dr. Gordon one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List".





DENNIS PURCELL

Founder & Senior Advisor, Aisling Capital

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") for over five years.

MELINDA RICHTER

Global Head, Johnson & Johnson Innovation — JLABS

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.





CAMILLE SAMUELS

Partner, Venrock

Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Biolux, Corvidia, Iris, Unity (UBX), and XCaliber. Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix). Before Versant, she was responsible for business development at Tularik (acquired by Amgen). During her early career, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant at LEK Consulting. Cami earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.

BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

May 3-4, 2022 | Metro Toronto Convention Centre



#BBHIC2019

Panel

Commercial-Stage
are companies

ntt 2:30



